CRISPR–Cas therapies targeting bacteria
Source abstract
Abstract
Technologies derived from the CRISPR (clustered regularly interspaced short palindromic repeats)–Cas immune system of prokaryotes have revolutionized our ability to cleave and modify target nucleic acid sequences. In addition to the use of CRISPR–Cas tools for the editing of human genes, they can also be designed to target pathogenic and commensal bacteria that colonize the body, offering new pathways for the treatment of infections and microbiome modulation. In this Review, we explore how the CRISPR–Cas toolbox can be engineered to kill or modify specific bacteria. We discuss DNA-targeting and RNA-targeting strategies, outlining how these can be applied to disarm bacteria by removing, modifying or silencing specific genes. Furthermore, we examine the delivery of CRISPR–Cas tools by bacteriophages and through conjugation and explore intracellular barriers to CRISPR–Cas tool maintenance and expression. Finally, we highlight therapeutic opportunities in the treatment of infectious diseases and for the modification of the microbiome, outlining progress and challenges in translating these approaches into clinical applications.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CRISPR and Genetic Engineering · Insect symbiosis and bacterial influences · Cytomegalovirus and herpesvirus research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).10.1016/S0140-6736(21)02724-0 ↗
2. Okeke, I. N. et al. The scope of the antimicrobial resistance challenge. Lancet 403, 2426–2438 (2024).10.1016/S0140-6736(24)00876-6 ↗
3. Fan, Y. & Pedersen, O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. 19, 55–71 (2021).10.1038/s41579-020-0433-9 ↗
4. Hou, K. et al. Microbiota in health and diseases. Signal. Transduct. Target. Ther. 7, 135 (2022).10.1038/s41392-022-00974-4 ↗
5. Pirnay, J.-P. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat. Microbiol. 9, 1434–1453 (2024).10.1038/s41564-024-01705-x ↗
6. Lei, M., Jayaraman, A., Deventer, J. A. V. & Lee, K. Engineering selectively targeting antimicrobial peptides. Annu. Rev. Biomed. Eng. 23, 339–357 (2021).10.1146/annurev-bioeng-010220-095711 ↗
7. Altae-Tran, H. et al. Uncovering the functional diversity of rare CRISPR-Cas systems with deep terascale clustering. Science 382, eadi1910 (2023).10.1126/science.adi1910 ↗
8. Makarova, K. S. et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat. Rev. Microbiol. 18, 67–83 (2020).10.1038/s41579-019-0299-x ↗
9. Nussenzweig, P. M. & Marraffini, L. A. Molecular mechanisms of CRISPR-Cas immunity in bacteria. Annu. Rev. Genet. 54, 93–120 (2020).10.1146/annurev-genet-022120-112523 ↗
10. Rodrigues, M., McBride, S. W., Hullahalli, K., Palmer, K. L. & Duerkop, B. A. Conjugative delivery of CRISPR-Cas9 for the selective depletion of antibiotic-resistant Enterococci. Antimicrob. Agents Chemother. 63, e01454-19 (2019).10.1128/AAC.01454-19 ↗
11. Bikard, D. et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32, 1146–1150 (2014).10.1038/nbt.3043 ↗
12. Citorik, R. J., Mimee, M. & Lu, T. K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32, 1141–1145 (2014).10.1038/nbt.3011 ↗
13. Lam, K. N. et al. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep. 37, 109930 (2021).10.1016/j.celrep.2021.109930 ↗
14. Park, J. Y. et al. Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus. Sci. Rep. 7, 44929 (2017).10.1038/srep44929 ↗
15. Ram, G., Ross, H. F., Novick, R. P., Rodriguez-Pagan, I. & Jiang, D. Conversion of staphylococcal pathogenicity islands to CRISPR-carrying antibacterial agents that cure infections in mice. Nat. Biotechnol. 36, 971–976 (2018).10.1038/nbt.4203 ↗
16. Neil, K. et al. High-efficiency delivery of CRISPR-Cas9 by engineered probiotics enables precise microbiome editing. Mol. Syst. Biol. 17, e10335 (2021).10.15252/msb.202110335 ↗
17. Jin, W.-B. et al. Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome. Cell 185, 547–562.e22 (2022).10.1016/j.cell.2021.12.035 ↗
18. Zhou, Y. et al. Exploiting a conjugative endogenous CRISPR-Cas3 system to tackle multidrug-resistant Klebsiella pneumoniae. eBioMedicine 88, 104445 (2023).10.1016/j.ebiom.2023.104445 ↗
19. Selle, K. et al. In vivo targeting of clostridioides difficile using phage-delivered CRISPR-Cas3 antimicrobials. mBio 11, e00019-20 (2020).10.1128/mBio.00019-20 ↗
20. Gencay, Y. E. et al. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice. Nat. Biotechnol. 42, 265–274 (2023).10.1038/s41587-023-01759-y ↗
21. Cui, L. & Bikard, D. Consequences of Cas9 cleavage in the chromosome of Escherichia coli. Nucleic Acids Res. 44, 4243–4251 (2016).10.1093/nar/gkw223 ↗
22. Csörgő, B. et al. A compact Cascade–Cas3 system for targeted genome engineering. Nat. Methods 17, 1183–1190 (2020).10.1038/s41592-020-00980-w ↗
23. Vercoe, R. B. et al. Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands. PLoS Genet. 9, e1003454 (2013).10.1371/journal.pgen.1003454 ↗
24. Bernheim, A., Bikard, D., Touchon, M. & Rocha, E. P. C. A matter of background: DNA repair pathways as a possible cause for the sparse distribution of CRISPR-Cas systems in bacteria. Philos. Trans. R. Soc. B Biol. Sci. 374, 20180088 (2019).10.1098/rstb.2018.0088 ↗
25. Vialetto, E. et al. Systematic interrogation of CRISPR antimicrobials in Klebsiella pneumoniae reveals nuclease-, guide- and strain-dependent features influencing antimicrobial activity. Nucleic Acids Res. 52, 6079–6091 (2024).10.1093/nar/gkae281 ↗
26. Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–771 (2015).10.1016/j.cell.2015.09.038 ↗
27. Stella, G. & Marraffini, L. Type III CRISPR-Cas: beyond the Cas10 effector complex. Trends Biochem. Sci. 49, 28–37 (2024).10.1016/j.tibs.2023.10.006 ↗
28. Rostøl, J. T. et al. The Card1 nuclease provides defence during type III CRISPR immunity. Nature 590, 624–629 (2021).10.1038/s41586-021-03206-x ↗
29. Marraffini, L. A. & Sontheimer, E. J. Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature 463, 568–571 (2010).10.1038/nature08703 ↗
30. Pyenson, N. C., Gayvert, K., Varble, A., Elemento, O. & Marraffini, L. A. Broad targeting specificity during bacterial type III CRISPR-Cas immunity constrains viral escape. Cell Host Microbe 22, 343–353.e3 (2017).10.1016/j.chom.2017.07.016 ↗
31. Abudayyeh, O. O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, eaaf5573 (2016).10.1126/science.aaf5573 ↗
32. Vialetto, E. et al. A target expression threshold dictates invader defense and prevents autoimmunity by CRISPR-Cas13. Cell Host Microbe 30, 1151–1162.e6 (2022).10.1016/j.chom.2022.05.013 ↗
33. Kiga, K. et al. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nat. Commun. 11, 2934 (2020).10.1038/s41467-020-16731-6 ↗
34. Dmytrenko, O. et al. Cas12a2 elicits abortive infection through RNA-triggered destruction of dsDNA. Nature 613, 588–594 (2023).10.1038/s41586-022-05559-3 ↗
35. Selle, K., Klaenhammer, T. R. & Barrangou, R. CRISPR-based screening of genomic island excision events in bacteria. Proc. Natl Acad. Sci. USA 112, 8076–8081 (2015).10.1073/pnas.1508525112 ↗
36. Wang, P. et al. Eliminating mcr-1-harbouring plasmids in clinical isolates using the CRISPR/Cas9 system. J. Antimicrob. Chemother. 74, 2559–2565 (2019).10.1093/jac/dkz246 ↗
37. Yosef, I., Manor, M., Kiro, R. & Qimron, U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl Acad. Sci. USA 112, 7267–7272 (2015).10.1073/pnas.1500107112 ↗
38. Long, T.-F. et al. Innovative delivery system combining CRISPR-Cas12f for combatting antimicrobial resistance in gram-negative bacteria. ACS Synth. Biol. 13, 1831–1841 (2024).10.1021/acssynbio.4c00112 ↗
39. Paterson, D. L. & Bonomo, R. A. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18, 657–686 (2005).10.1128/CMR.18.4.657-686.2005 ↗
40. Tagliaferri, T. L. et al. Exploring the potential of CRISPR-Cas9 under challenging conditions: facing high-copy plasmids and counteracting beta-lactam resistance in clinical strains of Enterobacteriaceae. Front. Microbiol. 11, 578 (2020).10.3389/fmicb.2020.00578 ↗
41. Wongpayak, P., Meesungnoen, O., Saejang, S. & Subsoontorn, P. A highly effective and self-transmissible CRISPR antimicrobial for elimination of target plasmids without antibiotic selection. PeerJ 9, e11996 (2021).10.7717/peerj.11996 ↗
42. Dong, H., Xiang, H., Mu, D., Wang, D. & Wang, T. Exploiting a conjugative CRISPR/Cas9 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli. Int. J. Antimicrob. Agents 53, 1–8 (2019).10.1016/j.ijantimicag.2018.09.017 ↗
43. Li, P. et al. Targeted elimination of bla NDM-5 gene in Escherichia coli by conjugative CRISPR-Cas9 system. Infect. Drug Resist. 15, 1707–1716 (2022).10.2147/IDR.S357470 ↗
44. Walker-Sünderhauf, D. et al. Removal of AMR plasmids using a mobile, broad host-range CRISPR-Cas9 delivery tool. Microbiology 169, 001334 (2023).
45. Bakkeren, E. et al. Salmonella persisters promote the spread of antibiotic resistance plasmids in the gut. Nature 573, 276–280 (2019).10.1038/s41586-019-1521-8 ↗
46. Quinones-Olvera, N. et al. Diverse and abundant phages exploit conjugative plasmids. Nat. Commun. 15, 3197 (2024).10.1038/s41467-024-47416-z ↗
47. Jurėnas, D., Fraikin, N., Goormaghtigh, F. & Van Melderen, L. Biology and evolution of bacterial toxin–antitoxin systems. Nat. Rev. Microbiol. 20, 335–350 (2022).10.1038/s41579-021-00661-1 ↗
48. Reuter, A. et al. Targeted-antibacterial-plasmids (TAPs) combining conjugation and CRISPR/Cas systems achieve strain-specific antibacterial activity. Nucleic Acids Res. 49, 3584–3598 (2021).10.1093/nar/gkab126 ↗
49. Benz, F. et al. Type IV-A3 CRISPR-Cas systems drive inter-plasmid conflicts by acquiring spacers in trans. Cell Host Microbe 32, 875–886.e9 (2024).10.1016/j.chom.2024.04.016 ↗
50. Mamontov, V. et al. Persistence of plasmids targeted by CRISPR interference in bacterial populations. Proc. Natl Acad. Sci. USA 119, e2114905119 (2022).10.1073/pnas.2114905119 ↗
51. Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L. A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 31, 233–239 (2013).10.1038/nbt.2508 ↗
52. Jiang, Y. et al. Multigene editing in the Escherichia coli genome via the CRISPR-Cas9 system. Appl. Environ. Microbiol. 81, 2506–2514 (2015).10.1128/AEM.04023-14 ↗
53. Reisch, C. R. & Prather, K. L. J. The no-SCAR (Scarless Cas9 Assisted Recombineering) system for genome editing in Escherichia coli. Sci. Rep. 5, 15096 (2015).10.1038/srep15096 ↗
54. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).10.1038/nature17946 ↗
55. Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).10.1038/nature24644 ↗
56. Brödel, A. K. et al. In situ targeted base editing of bacteria in the mouse gut. Nature 632, 877–884 (2024).10.1038/s41586-024-07681-w ↗
57. Guzmán-Herrador, D. L., Fernández-Gómez, A., Depardieu, F., Bikard, D. & Llosa, M. In vivo delivery of functional Cas:DNA nucleoprotein complexes into recipient bacteria through a type IV secretion system. Proc. Natl Acad. Sci. USA 121, e2408509121 (2024).10.1073/pnas.2408509121 ↗
58. Nethery, M. A., Hidalgo-Cantabrana, C., Roberts, A. & Barrangou, R. CRISPR-based engineering of phages for in situ bacterial base editing. Proc. Natl Acad. Sci. USA 119, e2206744119 (2022).10.1073/pnas.2206744119 ↗
59. Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).10.1038/s41586-019-1711-4 ↗
60. Gelsinger, D. R. et al. Bacterial genome engineering using CRISPR-associated transposases. Nat. Protoc. 19, 752–790 (2024).10.1038/s41596-023-00927-3 ↗
61. Rubin, B. E. et al. Species- and site-specific genome editing in complex bacterial communities. Nat. Microbiol. 7, 34–47 (2022).10.1038/s41564-021-01014-7 ↗
62. Bikard, D. et al. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 41, 7429–7437 (2013).10.1093/nar/gkt520 ↗
63. Qi, L. S. et al. Repurposing CRISPR as an RNA-γuided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).10.1016/j.cell.2013.02.022 ↗
64. Luo, M. L., Mullis, A. S., Leenay, R. T. & Beisel, C. L. Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression. Nucleic Acids Res. 43, 674–681 (2015).10.1093/nar/gku971 ↗
65. Kim, S. K. et al. Efficient transcriptional gene repression by type V-A CRISPR-Cpf1 from Eubacterium eligens. ACS Synth. Biol. 6, 1273–1282 (2017).10.1021/acssynbio.6b00368 ↗
66. Vigouroux, A. & Bikard, D. CRISPR tools to control gene expression in bacteria. Microbiol. Mol. Biol. Rev. 84, e00077-19 (2020).10.1128/MMBR.00077-19 ↗
67. Zebec, Z., Manica, A., Zhang, J., White, M. F. & Schleper, C. CRISPR-mediated targeted mRNA degradation in the archaeon Sulfolobus solfataricus. Nucleic Acids Res. 42, 5280–5288 (2014).10.1093/nar/gku161 ↗
68. Adler, B. A. et al. Genome-wide characterization of diverse bacteriophages enabled by RNA-binding CRISPRi. Nat. Microbiol. 10, 694–709 (2025).10.1038/s41564-025-01935-7 ↗
69. Charles, E. J. et al. Engineering improved Cas13 effectors for targeted post-transcriptional regulation of gene expression. Preprint at bioRxiv https://doi.org/10.1101/2021.05.26.445687 (2021).10.1101/2021.05.26.445687 ↗
70. Kim, G. et al. Tunable translation-level CRISPR interference by dCas13 and engineered gRNA in bacteria. Nat. Commun. 15, 5319 (2024).10.1038/s41467-024-49642-x ↗
71. Madigan, V., Zhang, F. & Dahlman, J. E. Drug delivery systems for CRISPR-based genome editors. Nat. Rev. Drug Discov. 22, 875–894 (2023).10.1038/s41573-023-00762-x ↗
72. Bikard, D., Hatoum-Aslan, A., Mucida, D. & Marraffini, L. A. CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe 12, 177–186 (2012).10.1016/j.chom.2012.06.003 ↗
73. Gomaa, A. A. et al. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio 5, e00928-13 (2014).10.1128/mBio.00928-13 ↗
74. Shkoporov, A. N. et al. Viral biogeography of the mammalian gut and parenchymal organs. Nat. Microbiol. 7, 1301–1311 (2022).10.1038/s41564-022-01178-w ↗
75. López-Pérez, M., Haro-Moreno, J. M., Gonzalez-Serrano, R., Parras-Moltó, M. & Rodriguez-Valera, F. Genome diversity of marine phages recovered from Mediterranean metagenomes: size matters. PLoS Genet. 13, e1007018 (2017).10.1371/journal.pgen.1007018 ↗
76. Kauffman, K. M. et al. Resolving the structure of phage–bacteria interactions in the context of natural diversity. Nat. Commun. 13, 372 (2022).10.1038/s41467-021-27583-z ↗
77. Bertozzi Silva, J., Storms, Z. & Sauvageau, D. Host receptors for bacteriophage adsorption. FEMS Microbiol. Lett. 363, fnw002 (2016).10.1093/femsle/fnw002 ↗
78. Buffet, A., Rocha, E. P. C. & Rendueles, O. Nutrient conditions are primary drivers of bacterial capsule maintenance in Klebsiella. Proc. R. Soc. B Biol. Sci. 288, 20202876 (2021).10.1098/rspb.2020.2876 ↗
79. Klumpp, J., Dunne, M. & Loessner, M. J. A perfect fit: bacteriophage receptor-binding proteins for diagnostic and therapeutic applications. Curr. Opin. Microbiol. 71, 102240 (2023).10.1016/j.mib.2022.102240 ↗
80. Latka, A. et al. Engineering the modular receptor-binding proteins of Klebsiella phages switches their capsule serotype specificity. mBio 12, e00455-21 (2021).10.1128/mBio.00455-21 ↗
81. Ando, H., Lemire, S., Pires, D. P. & Lu, T. K. Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst. 1, 187–196 (2015).10.1016/j.cels.2015.08.013 ↗
82. Apjok, G. et al. Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. Nat. Microbiol. 8, 410–423 (2023).
83. Cunliffe, T. G., Parker, A. L. & Jaramillo, A. Pseudotyping bacteriophage P2 tail fibers to extend the host range for biomedical applications. ACS Synth. Biol. 10, 3207–3215 (2022).10.1021/acssynbio.1c00629 ↗
84. Dunne, M. et al. Reprogramming bacteriophage host range through structure-guided design of chimeric receptor binding proteins. Cell Rep. 29, 1336–1350.e4 (2019).10.1016/j.celrep.2019.09.062 ↗
85. Lam, C. N. et al. A tail fiber engineering platform for improved bacterial transduction-based diagnostic reagents. ACS Synth. Biol. 10, 1292–1299 (2021).10.1021/acssynbio.1c00036 ↗
86. Mahichi, F., Synnott, A. J., Yamamichi, K., Osada, T. & Tanji, Y. Site‐specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity. FEMS Microbiol. Lett. 295, 211–217 (2009).10.1111/j.1574-6968.2009.01588.x ↗
87. Yosef, I., Goren, M. G., Globus, R., Molshanski-Mor, S. & Qimron, U. Extending the host range of bacteriophage particles for DNA transduction. Mol. Cell 66, 721–728.e3 (2017).10.1016/j.molcel.2017.04.025 ↗
88. Montag, D., Schwarz, H. & Henning, U. A component of the side tail fiber of Escherichia coli bacteriophage lambda can functionally replace the receptor-recognizing part of a long tail fiber protein of the unrelated bacteriophage T4. J. Bacteriol. 171, 4378–4384 (1989).10.1128/jb.171.8.4378-4384.1989 ↗
89. Nobrega, F. L. et al. Targeting mechanisms of tailed bacteriophages. Nat. Rev. Microbiol. 16, 760–773 (2018).10.1038/s41579-018-0070-8 ↗
90. Ibarra-Chávez, R. Rebooting synthetic phage-inducible chromosomal islands: one method to forge them all. Biodes. Res. 2020, 5783064 (2020).10.34133/2020/5783064 ↗
91. Huss, P., Meger, A., Leander, M., Nishikawa, K. K. & Raman, S. Mapping the functional landscape of the receptor binding domain of T7 bacteriophage by deep mutational scanning. eLife 10, e63775 (2021).10.7554/eLife.63775 ↗
92. Liang, J., Zhang, H., Tan, Y. L., Zhao, H. & Ang, E. L. Directed evolution of replication-competent double-stranded DNA bacteriophage toward new host specificity. ACS Synth. Biol. 11, 634–643 (2022).10.1021/acssynbio.1c00319 ↗
93. Yehl, K. et al. Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis. Cell 179, 459–469.e9 (2019).10.1016/j.cell.2019.09.015 ↗
94. Liyanagedera, S. B. W. et al. SpyPhage: a cell-free TXTL platform for rapid engineering of targeted phage therapies. ACS Synth. Biol. 11, 3330–3342 (2022).10.1021/acssynbio.2c00244 ↗
95. Levrier, A. et al. PHEIGES: all-cell-free phage synthesis and selection from engineered genomes. Nat. Commun. 15, 2223 (2024).10.1038/s41467-024-46585-1 ↗
96. Favor, A. H., Llanos, C. D., Youngblut, M. D. & Bardales, J. A. Optimizing bacteriophage engineering through an accelerated evolution platform. Sci. Rep. 10, 13981 (2020).10.1038/s41598-020-70841-1 ↗
97. Nobrega, F. L. et al. Genetically manipulated phages with improved pH resistance for oral administration in veterinary medicine. Sci. Rep. 6, 39235 (2016).10.1038/srep39235 ↗
98. Kittleson, J. T., DeLoache, W., Cheng, H.-Y. & Anderson, J. C. Scalable plasmid transfer using engineered P1-based phagemids. ACS Synth. Biol. 1, 583–589 (2012).10.1021/sb300054p ↗
99. Lu, T. K. & Collins, J. J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl Acad. Sci. USA 106, 4629–4634 (2009).10.1073/pnas.0800442106 ↗
100. Tridgett, M., Ababi, M., Osgerby, A., Garcia, R. R. & Jaramillo, A. Engineering bacteria to produce pure phage-like particles for gene delivery. ACS Synth. Biol. 10, 107–114 (2021).10.1021/acssynbio.0c00467 ↗